Cargando…

SUN-LB95 Developing a Highly Equivalent Non-Competitive Chemiluminescence Immunoassay Aldosterone Measurement to LC/MS

Background Measurement of plasma aldosterone and renin concentration, or activity, is useful for selecting antihypertensive agents anddetecting hyperaldosteronism in hypertensive patients. However, it takes several days to get results even if measured by inaccurateradioimmunoassay, or we must accept...

Descripción completa

Detalles Bibliográficos
Autores principales: Satoh, Fumitoshi, Ono, Yoshikiyo, Omata, Kei, Tezuka, Yuta, Yamanami, Hiroaki, Morimoto, Ryo, Kojima, Satoshi, Sasano, Hironobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208561/
http://dx.doi.org/10.1210/jendso/bvaa046.2100
_version_ 1783530874241810432
author Satoh, Fumitoshi
Ono, Yoshikiyo
Omata, Kei
Tezuka, Yuta
Yamanami, Hiroaki
Morimoto, Ryo
Kojima, Satoshi
Sasano, Hironobu
author_facet Satoh, Fumitoshi
Ono, Yoshikiyo
Omata, Kei
Tezuka, Yuta
Yamanami, Hiroaki
Morimoto, Ryo
Kojima, Satoshi
Sasano, Hironobu
author_sort Satoh, Fumitoshi
collection PubMed
description Background Measurement of plasma aldosterone and renin concentration, or activity, is useful for selecting antihypertensive agents anddetecting hyperaldosteronism in hypertensive patients. However, it takes several days to get results even if measured by inaccurateradioimmunoassay, or we must accept high-cost LC/MS, and development of a more rapid and accurate substitute has been long hoped. We havedeveloped a novel, fully-automated, high-quantitative noncompetitive chemiluminescence immunoassay (NC-CLEIA) for detecting aldosterone inserum and plasma, and its performance is evaluated as compared to LC/MS measurement. Methods Recently a unique anti-metatype antibody,which recognizes the immunocomplex of aldosterone and its monoclonal antibody, was established. Using this antibody for sensing permittedthe construction of non-competitive assay for the detection of aldosterone. The reaction protocol of novel aldosterone assay is the following. Inthe 1st reaction, aldosterone in patient’s sample is captured on anti-body coated magnetic particles. Alkaline phosphatase-conjugated antimetatypeantibody is added and incubated as 2nd reaction following a wash. Then substrate solution is added after washing immunocomplex.The resulting reaction signals are proportional to the amount of aldosterone in the sample allowing quantitative determination of in serum orplasma sample. The overall reaction is completed within 30 min. Results Limit of blank (LoB), limit of detection (LoD) and limit of quantitation(LoQ) of our NC-CLEIA aldosterone assay were 0.09 ng/dL, 0.21 ng/dL and 0.57 ng/dL, respectively. NC-CLEIA aldosterone measurements werelinearly well correlated with LC/MS aldosterone measurements (N = 130, y = 1.027x - 0.23 ng/dL, Spearman’s ρ = 0.996, P< 0.0001). Bland-Altmanplot analysis between NC-CLEIA and LC-MS/MS of aldosterone revealed a bias of 0.40 ng/dL with the limits of agreement of -4.60 and 5.41 ng/dLwith 95% confidence interval. Conclusion Our novel NC-CLEIA aldosterone assay was well-correlated and had only a very low bias with LC-MS/MSmethod and also was able to accurately quantify low level samples even in essential hypertension patients. This aldosterone assay can be a most equivalent to LC-MS/MS measurement with a low cost of 12 $ and a short measuring time of 30 minutes.
format Online
Article
Text
id pubmed-7208561
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-72085612020-05-13 SUN-LB95 Developing a Highly Equivalent Non-Competitive Chemiluminescence Immunoassay Aldosterone Measurement to LC/MS Satoh, Fumitoshi Ono, Yoshikiyo Omata, Kei Tezuka, Yuta Yamanami, Hiroaki Morimoto, Ryo Kojima, Satoshi Sasano, Hironobu J Endocr Soc Cardiovascular Endocrinology Background Measurement of plasma aldosterone and renin concentration, or activity, is useful for selecting antihypertensive agents anddetecting hyperaldosteronism in hypertensive patients. However, it takes several days to get results even if measured by inaccurateradioimmunoassay, or we must accept high-cost LC/MS, and development of a more rapid and accurate substitute has been long hoped. We havedeveloped a novel, fully-automated, high-quantitative noncompetitive chemiluminescence immunoassay (NC-CLEIA) for detecting aldosterone inserum and plasma, and its performance is evaluated as compared to LC/MS measurement. Methods Recently a unique anti-metatype antibody,which recognizes the immunocomplex of aldosterone and its monoclonal antibody, was established. Using this antibody for sensing permittedthe construction of non-competitive assay for the detection of aldosterone. The reaction protocol of novel aldosterone assay is the following. Inthe 1st reaction, aldosterone in patient’s sample is captured on anti-body coated magnetic particles. Alkaline phosphatase-conjugated antimetatypeantibody is added and incubated as 2nd reaction following a wash. Then substrate solution is added after washing immunocomplex.The resulting reaction signals are proportional to the amount of aldosterone in the sample allowing quantitative determination of in serum orplasma sample. The overall reaction is completed within 30 min. Results Limit of blank (LoB), limit of detection (LoD) and limit of quantitation(LoQ) of our NC-CLEIA aldosterone assay were 0.09 ng/dL, 0.21 ng/dL and 0.57 ng/dL, respectively. NC-CLEIA aldosterone measurements werelinearly well correlated with LC/MS aldosterone measurements (N = 130, y = 1.027x - 0.23 ng/dL, Spearman’s ρ = 0.996, P< 0.0001). Bland-Altmanplot analysis between NC-CLEIA and LC-MS/MS of aldosterone revealed a bias of 0.40 ng/dL with the limits of agreement of -4.60 and 5.41 ng/dLwith 95% confidence interval. Conclusion Our novel NC-CLEIA aldosterone assay was well-correlated and had only a very low bias with LC-MS/MSmethod and also was able to accurately quantify low level samples even in essential hypertension patients. This aldosterone assay can be a most equivalent to LC-MS/MS measurement with a low cost of 12 $ and a short measuring time of 30 minutes. Oxford University Press 2020-05-08 /pmc/articles/PMC7208561/ http://dx.doi.org/10.1210/jendso/bvaa046.2100 Text en © Endocrine Society 2020. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Cardiovascular Endocrinology
Satoh, Fumitoshi
Ono, Yoshikiyo
Omata, Kei
Tezuka, Yuta
Yamanami, Hiroaki
Morimoto, Ryo
Kojima, Satoshi
Sasano, Hironobu
SUN-LB95 Developing a Highly Equivalent Non-Competitive Chemiluminescence Immunoassay Aldosterone Measurement to LC/MS
title SUN-LB95 Developing a Highly Equivalent Non-Competitive Chemiluminescence Immunoassay Aldosterone Measurement to LC/MS
title_full SUN-LB95 Developing a Highly Equivalent Non-Competitive Chemiluminescence Immunoassay Aldosterone Measurement to LC/MS
title_fullStr SUN-LB95 Developing a Highly Equivalent Non-Competitive Chemiluminescence Immunoassay Aldosterone Measurement to LC/MS
title_full_unstemmed SUN-LB95 Developing a Highly Equivalent Non-Competitive Chemiluminescence Immunoassay Aldosterone Measurement to LC/MS
title_short SUN-LB95 Developing a Highly Equivalent Non-Competitive Chemiluminescence Immunoassay Aldosterone Measurement to LC/MS
title_sort sun-lb95 developing a highly equivalent non-competitive chemiluminescence immunoassay aldosterone measurement to lc/ms
topic Cardiovascular Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208561/
http://dx.doi.org/10.1210/jendso/bvaa046.2100
work_keys_str_mv AT satohfumitoshi sunlb95developingahighlyequivalentnoncompetitivechemiluminescenceimmunoassayaldosteronemeasurementtolcms
AT onoyoshikiyo sunlb95developingahighlyequivalentnoncompetitivechemiluminescenceimmunoassayaldosteronemeasurementtolcms
AT omatakei sunlb95developingahighlyequivalentnoncompetitivechemiluminescenceimmunoassayaldosteronemeasurementtolcms
AT tezukayuta sunlb95developingahighlyequivalentnoncompetitivechemiluminescenceimmunoassayaldosteronemeasurementtolcms
AT yamanamihiroaki sunlb95developingahighlyequivalentnoncompetitivechemiluminescenceimmunoassayaldosteronemeasurementtolcms
AT morimotoryo sunlb95developingahighlyequivalentnoncompetitivechemiluminescenceimmunoassayaldosteronemeasurementtolcms
AT kojimasatoshi sunlb95developingahighlyequivalentnoncompetitivechemiluminescenceimmunoassayaldosteronemeasurementtolcms
AT sasanohironobu sunlb95developingahighlyequivalentnoncompetitivechemiluminescenceimmunoassayaldosteronemeasurementtolcms